This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ek, I. Articles by Wahrenberg, H. Search for Related Content PubMed PubMed Citation Articles by Ek, I. Articles by Wahrenberg, H.

Impaired Adipocyte Lipolysis in Nonobese Women with the Polycystic Ovary Syndrome: A Possible Link to Insulin Resistance?¹

Departments of Medicine and Gynecology and Obstetrics, and the Research Center, Huddinge University Hospital, Karolinska Institute, Huddinge, Sweden

Address all correspondence and requests for reprints to: Hans Wahrenberg, M.D., Division of Endocrinology and Metabolism, Department of Medicine M63, Huddinge Hospital, Karolinska Institute, S-141 86 Huddinge, Sweden.

The polycystic ovary syndrome (PCOS) is the most common hyperandrogenic disorder among women and is characterized by metabolic and cardiovascular aberrations similar to those seen in the so-called insulin resistance syndrome. The regulation of lipolysis was investigated in isolated abdominal sc adipocytes from 10 nonobese women with PCOS and in 11 age- and body mass index-matched healthy women. Eight PCOS women were reinvestigated after 3 months of treatment with combined oral contraceptives containing ethinyl estradiol and norethisterone, which normalized hyperandrogenicity. The PCOS women showed a marked resistance to the lipolytic effect of noradrenaline due to defects at two different levels in the lipolytic cascade: first, a 7-fold reduction in sensitivity to the ß₂-selective agonist terbutaline (P < 0.005), which could be ascribed to a 50% lower ß₂-adrenoceptor density (P < 0.02) as determined with radioligand binding; there was no difference with regard to dobutamine (ß₁) or clonidine (₂-sensitivity) or ß₁-adrenoceptor density; second, the maximum lipolytic response was also 35% lower (P < 0.02) in the PCOS women compared to that in the healthy women. This was seen with all ß-adrenergic agonists and the postreceptor-acting agents forskolin (activating adenylyl cyclase) and dibutyryl cAMP (activating protein kinase). Neither ß₂-adrenoceptor sensitivity or density nor the reduced lipolytic responsiveness was restored by 3 months of oral contraceptives treatment. The results indicate the existence of a marked impairment of catecholamine-induced lipolysis in nonobese PCOS women displaying early features of the insulin resistance syndrome due to multiple lipolysis defects as a lower ß₂-adrenoceptor density and reduced function of the protein kinase, hormone-sensitive lipase complex. These lipolysis defects are identical to those observed in the insulin resistance (metabolic) syndrome and could be a primary pathogenic mechanism for the development of these disorders.

This article has been cited by other articles:

				C. Moro, M. Pasarica, K. Elkind-Hirsch, and L. M. Redman Aerobic Exercise Training Improves Atrial Natriuretic Peptide and Catecholamine-Mediated Lipolysis in Obese Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2579 - 2586. [Abstract] [Full Text] [PDF]

				V. R. Aroda, T. P. Ciaraldi, P. Burke, S. Mudaliar, P. Clopton, S. Phillips, R. J. Chang, and R. R. Henry Metabolic and Hormonal Changes Induced by Pioglitazone in Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Clinical Trial J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 469 - 476. [Abstract] [Full Text] [PDF]

				K. E. S. Salley, E. P. Wickham, K. I. Cheang, P. A. Essah, N. W. Karjane, and J. E. Nestler POSITION STATEMENT: Glucose Intolerance in Polycystic Ovary Syndrome A Position Statement of the Androgen Excess Society J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4546 - 4556. [Abstract] [Full Text] [PDF]

				B. K. Tan, J. Chen, J. E. Digby, S. D. Keay, C. R. Kennedy, and H. S. Randeva Increased Visfatin Messenger Ribonucleic Acid and Protein Levels in Adipose Tissue and Adipocytes in Women with Polycystic Ovary Syndrome: Parallel Increase in Plasma Visfatin J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5022 - 5028. [Abstract] [Full Text] [PDF]

				A. Corbould, Y.-B. Kim, J. F. Youngren, C. Pender, B. B. Kahn, A. Lee, and A. Dunaif Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling Am J Physiol Endocrinol Metab, May 1, 2005; 288(5): E1047 - E1054. [Abstract] [Full Text] [PDF]

				G. Faulds, M. Ryden, I. Ek, H. Wahrenberg, and P. Arner Mechanisms behind Lipolytic Catecholamine Resistance of Subcutaneous Fat Cells in the Polycystic Ovarian Syndrome J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2269 - 2273. [Abstract] [Full Text] [PDF]

				R. Azziz Polycystic Ovary Syndrome, Insulin Resistance, and Molecular Defects of Insulin Signaling J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4085 - 4087. [Full Text] [PDF]

				I. Ek, P. Arner, M. Ryden, C. Holm, A. Thorne, J. Hoffstedt, and H. Wahrenberg A Unique Defect in the Regulation of Visceral Fat Cell Lipolysis in the Polycystic Ovary Syndrome as an Early Link to Insulin Resistance Diabetes, February 1, 2002; 51(2): 484 - 492. [Abstract] [Full Text] [PDF]

				L. Ibáñez, N. Potau, M. V. Marcos, and F. de Zegher Treatment of Hirsutism, Hyperandrogenism, Oligomenorrhea, Dyslipidemia, and Hyperinsulinism in Nonobese, Adolescent Girls: Effect of Flutamide J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3251 - 3255. [Abstract] [Full Text]

				R. A. Lobo and E. Carmina The Importance of Diagnosing the Polycystic Ovary Syndrome Ann Intern Med, June 20, 2000; 132(12): 989 - 993. [Abstract] [Full Text] [PDF]

				C.-B. Book and A. Dunaif Selective Insulin Resistance in the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3110 - 3116. [Abstract] [Full Text]

				P. J.Marsden, A. P. Murdoch, and R. Taylor Adipocyte insulin action following ovulation in polycystic ovarian syndrome Hum. Reprod., September 1, 1999; 14(9): 2216 - 2222. [Abstract] [Full Text] [PDF]

				L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice The Insulin-Related Ovarian Regulatory System in Health and Disease Endocr. Rev., August 1, 1999; 20(4): 535 - 582. [Abstract] [Full Text] [PDF]

				E. Carmina and R. A. Lobo Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1897 - 1899. [Full Text]

				H. Wahrenberg, I. Ek, S. Reynisdottir, K. Carlström, A. Bergqvist, and P. Arner Divergent Effects of Weight Reduction and Oral Anticonception Treatment on Adrenergic Lipolysis Regulation in Obese Women with the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2182 - 2187. [Abstract] [Full Text]

				R. S. Legro, A. R. Kunselman, W. C. Dodson, and A. Dunaif Prevalence and Predictors of Risk for Type 2 Diabetes Mellitus and Impaired Glucose Tolerance in Polycystic Ovary Syndrome: A Prospective, Controlled Study in 254 Affected Women J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 165 - 169. [Abstract] [Full Text]

				E. Diamanti-Kandarakis, A. Mitrakou, S. Raptis, G. Tolis, and A. J. Duleba The Effect of a Pure Antiandrogen Receptor Blocker, Flutamide, on the Lipid Profile in the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2699 - 2705. [Abstract] [Full Text]